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Corticosteroid resistance is one of major barriers to effective management of chronic inﬂammatory re-
spiratory diseases, such as chronic obstructive pulmonary disease (COPD) and severe asthma. These
patients often experience exacerbations with viral and/or bacterial infection, which may cause con-
tinuous corticosteroid insensitive inﬂammation. In this study, we observed that repeated exposure of
lipopolysaccharide (LPS) intranasally attenuated the anti-inﬂammatory effects of the corticosteroid ﬂu-
ticasone propionate (FP) on neutrophils and CXCL1 levels in bronchoalveolar lavage (BAL) ﬂuid in an
in vivo murine model. Histone deacetylase-2 (HDAC2) and NF-E2 related factor 2 (Nrf2) levels in lungs
after LPS administration for 3 consecutive days were signiﬁcantly decreased to 38.976.3% (mean7SEM)
and 77.572.7% of the levels seen after only one day of LPS exposure, respectively. In addition, 3 days LPS
exposure resulted in an increase of Akt phosphorylation, indicating activation of the phosphoinositide-3-
kinase (PI3K) pathway by 4-fold in lungs compared with 1 day of exposure. Furthermore, combination
treatment with theophylline and FP signiﬁcantly decreased the neutrophil accumulation and CXCL1
concentrations in BAL ﬂuid from 22.571.8104 cells/mL and 214.6720.6 pg/mL to 7.970.5104
cells/mL and 61.9713.3 pg/mL, respectively. Combination treatment with IC87114, a selective PI3Kδ
inhibitor, and FP also signiﬁcantly decreased neutrophils and CXCL1 levels from 16.870.7104 cells/mL
and 182.474.6 pg/mL to 5.970.3104 cells/mL and 71.472.7 pg/mL, respectively. Taken together, re-
peated exposure of LPS causes corticosteroid-insensitive airway inﬂammation in vivo, and the corticos-
teroid-resistance induced by LPS is at least partly mediated through the activation of PI3Kδ, resulting in
decreased levels of HDAC2 and Nrf2. These ﬁndings provide a potentially new therapeutic approach to
COPD and severe asthma.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Reduced responsiveness to the anti-inﬂammatory effects of cor-
ticosteroids is one of the important clinical problems in chronic re-
spiratory inﬂammatory diseases, including COPD and severe asthma
[1–4]. Corticosteroids are one of the most effective therapeutic drugs
for asthma. However in COPD and some patients with asthma, cor-
ticosteroids fail to suppress chronic inﬂammation, even though some
reports suggested that high doses of systemic corticosteroids treat-
ment could attenuate chronic inﬂammation in COPD patients [1,4–6].B.V. This is an open access article u
zawa).
.Corticosteroids suppress inﬂammatory gene expression by re-
cruiting HDAC2 to the activated inﬂammatory transcriptional com-
plex, resulting in the deacetylation of histones and thus in-
ﬂammatory gene suppression [7]. In in vivo and in vitro models,
oxidative stress activates phosphoinositide-3-kinase-δ (PI3Kδ) and
reduces HDAC2 deacetylase activity [8,9]. In addition, cigarette smoke
extracts or oxidative stress induces HDAC2 phosphorylation, ubiqui-
tination, and nitration, resulting in HDAC2 degradation [10–12]. The
decreased activity and expression of HDAC2 induces glucocorticoid
receptor (GR) acetylation, resulting in loss of anti-inﬂammatory ef-
fects of corticosteroids and also a reduction in anti-oxidative defenses
due to a reduction in the key transcriptional regulator of anti-oxidant
genes, NF-E2 related factor 2 (Nrf2) [7,13–15].
COPD patients are prone to exacerbations, as a result of upper
respiratory tract virus infections such as rhinovirus, and/ornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mophilus inﬂuenzae [16–20]. In addition, lungs of COPD patients
are also chronically colonized by bacteria such as H. inﬂuenzae,
resulting in chronic exposure to endotoxins [21–24]. Therefore,
continuous inﬂammatory stimuli induced by viruses and/or bac-
teria contribute to the pathogenesis of COPD. In fact, we previously
reported that repeated stimulation by poly(I:C), an RNA virus in-
fection mimic, attenuated anti-inﬂammatory effects of corticos-
teroids [25]. However, there are few studies investigating the ef-
fects of repeated bacterial stimuli on corticosteroid sensitivity in
airways.
We hypothesized that repeated stimulation with LPS causes
corticosteroid-resistant inﬂammation in lungs. We examined the
impact of repeated intranasal LPS exposure on 3 consecutive days
on the anti-inﬂammatory effects of the corticosteroids ﬂuticasone
propionate (FP) in mice in vivo. We also investigated the role of
PI3K signaling in chronic LPS exposure.2. Materials and methods
2.1. Experimental animals
All animal studies were approved by the guidelines of the Ni-
hon University Animal Care and Use Committee. Speciﬁc patho-
gen-free male A/J mice aged 5 weeks were obtained from Sankyo
Labo Service Co Inc. (Tokyo, Japan). Mice were housed without
environmental enrichment in a climate-controlled room on a 12 h
light-dark cycle (2471 °C and 5575% humidity). Mice consumed
water and standard chow ad libitum.
2.2. Drug and chemicals
Fluticasone propionate (FP), lipopolysaccharide from Escherichia
coli (LPS), and propidium iodide were purchased from Sigma-Aldrich
(St. Louis, MO, USA). IC87114, an inhibitor of PI3Kδ, was purchased
from Chemdea (Ridgewood, NJ, USA). Fluorescein isothiocyanate
(FITC)-conjugated anti-neutrophils (7/4) antibody was purchased
from Acris Antibodies GmbH (Herford, Germany). Anti-Nrf2 (ab31163)
and anti-HDAC2 (ab12169) antibodies were purchased from Abcam
plc (Cambridge, UK). Anti-Akt antibody was purchased from
Cell Signaling Technology (Danvers, MA, USA). Anti-phospho-Akt
(Ser473), clone SK703, was purchased from Merck Millipore Co.
(Darmstadt, Germany). Anti-β-actin (AC-15) antibody was purcha-
sed from Sigma-Aldrich Co, LLC (St. Louis, MO, USA). HRP-conjugated
anti-rabbit IgG and anti-mouse IgG and ECL Plus were purchased
from GE Healthcare UK Ltd. (Buckingham, UK).
2.3. Drug treatment and LPS instillation
Mice were anesthetized with 2% isoﬂurane, then, LPS
(0.1 mg/mL, 40 μL/animal, twice daily) was administrated in-
tranasally (i.n.). The i.n. applications of LPS were repeated on the
second and third days. Mice were sacriﬁced 24 h after the i.n. LPS
administration on day 3 and the lungs were isolated and subjected
to further experiments. The 35 μL/animal of saline, FP (0.05 mg/mL
in saline), theophylline (2.0 mg/mL in saline), IC87114 (4.0 mg/mL
in saline) were administered i.n. 2 h before each LPS administra-
tion. In a pilot study, we conﬁrmed that 4.0 mg/mL of IC87114
almost completely inhibited PI3Kδ activity in lung of mouse (data
not shown).
2.4. Bronchial alveolar lavage (BAL) ﬂuid
At designated time points, BAL ﬂuid were collected after an-
esthetizing the mice, and then, placing a cannula into the tracheathrough which total 100 mL/kg was ﬂushed three times. The BAL
ﬂuid cells were collected by centrifugation (500 g, 4 °C, 10 min)
and hemolysis of contaminating erythrocytes induced by re-sus-
pending in 0.2% NaCl. After isotonization, by addition of the same
volume of 1.6% NaCl, the total number of BAL cells was counted
and aliquoted for ﬂow cytometry analysis.
2.5. Flow cytometry analysis
A BAL cell suspension was incubated with FITC-conjugated
anti-neutrophil antibody (clone 7/4, 2 μg/mL) and propidium io-
dide (2 μg/mL). The cells were subsequently analyzed using a ﬂow
cytometer (ALTRA II; Beckman Coulter, Tokyo, Japan) [25].
2.6. Immunoblotting and Enzyme-Linked Immunosorbent Assay
(ELISA)
For the detection of HDAC2, Nrf2, and β-actin, lung tissue was
homogenized in a lysis buffer containing 10 mM of Tris-HCl,
150 mM of NaCl, 0.5% of sodium deoxycholate, 1 mM of DTT, 0.5%
of Nonidet P-40, and a tablet of protease inhibitor cocktail (cOm-
plete Minis, Roche Diagnostic GmbH, Mannheim, Germany), ad-
justed to pH7.4. For the detection of Akt/p-Akt, lung tissue was
homogenized in a lysis buffer containing 50 mM of Tris-HCl,
150 mM of NaCl, 1% of Nonidet P-40, 0.25% of sodium deox-
ycholate, 1 mM of PMSF, a tablet of cOmplete Mini, and Pierce™
Phosphatase Inhibitor Mini Tabletss (Thermo Fisher Scientiﬁc,
Rockford, IL, USA), adjusted to pH7.4. The lysate containing 40 μg
of protein was separated by electrophoresis on 10% sodium do-
decyl sulfate (SDS) polyacrylamide gel, and then, transferred to
nitrocellulose membrane. The membrane was blocked with
blocking buffer (5% skim milk TBS/T (20 mM) for the detection of
HDAC2, Nrf2, and β-actin, or 1% BSA in TBS/T (20 mM) for the
detection of p-Akt/Akt) for 1hr at room temperature and incubated
with primary antibody (1:1000) in blocking buffer overnight at
4 °C. The membrane was washed with TBS/T and incubated with
secondary antibody for 2 h. After three additional washes, the
immunoreactive bands were visualized by ECL Plus on X-ray ﬁlm.
The CXCL1 concentrations in BAL ﬂuid supernatant were ana-
lyzed by using Quantikine mouse CXCL1/KC enzyme-linked im-
munosorbent assay kit (R&D systems Inc., Minneapolis, MN, USA).
2.7. Statistical analysis
Results are expressed as means7SEM. Multiple comparisons
were performed by analysis of variance followed by the Dunnett
multiple comparison test performed using the PRISM 6 software
program (GraphPad Software Inc., CA, USA). The comparison be-
tween two groups was performed by unpaired t-test with Welch
correction or Mann-Whitney test. Statistical signiﬁcance was de-
ﬁned as Po0.05.3. Results
3.1. Repeated dosing with i.n. LPS caused corticosteroid-insensitive
lung inﬂammation
To determine whether repeated i.n. administration of LPS in-
duces airway inﬂammation and reduces the anti-inﬂammatory
effects of FP, we examined the effects of FP in mice after intranasal
instillation of LPS on days 0, 1 and 2. Twenty four hours after the
last administration of LPS, the numbers of neutrophils in BAL ﬂuid
were analyzed by ﬂow cytometry. After i.n. LPS administration,
there was marked neutrophilia in BAL ﬂuid collected 24 h after 1,
2 or 3 consecutive days of challenge, and the number of
Fig. 1. Repeated exposure of LPS caused corticosteroid-insensitive airway neutrophilia in BAL ﬂuid. Mice were intranasally administered with LPS and FP. LPS and
0.05 mg/mL of FP were administered for 1–3 days (A). LPS and indicated dose of FP were treated for 1 (B) or 3 days (C), respectively. Twenty four hours after the last exposure
of LPS, mice were sacriﬁced. The neutrophil numbers in BAL ﬂuid were analyzed by ﬂow cytometry. Results represent mean7SEM (n¼3, ###Po0.001, compared with
control and vehicle group, ***Po0.001, compared with vehicle group and dosing groups).
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increase compared with LPS administration for 1 day. In mice with
exposure of LPS for one day(twice daily), i.n. treatment with
0.05 mg/mL of FP completely inhibited an increase in neutrophils
in BAL ﬂuid, but FP did not show any beneﬁcial effects on the level
of neutrophils in mice which received i.n. LPS in 3 consecutive
days (Fig. 1A). Further studies with FP (0.05, 0.5, and 1 mg/mL, i.n.)
conﬁrmed that the neutrophilia was not affected even by the
highest dose of FP, although FP signiﬁcantly reduced the neu-
trophilia after the LPS administration for 1 day, in a dose-depen-
dent manner (Fig. 1B and C).
CXCL1 concentrations increased signiﬁcantly in BAL ﬂuid from
mice which received LPS for 1, 2, and 3 days compared with
control, and LPS exposure on 3 consecutive days induced 1.7-fold
increase compared with exposure of LPS for 1 day. Although
treatment with 0.05 mg/mL of FP markedly suppressed theincrease of CXCL1 at 24 h after LPS exposure for 1 or 2 days
(Fig. 2A) in the model of 3 consecutive days LPS exposure, FP (0.05,
0.5, and 1 mg/mL) had no signiﬁcant effect on CXCL1 levels
(Fig. 2B).
3.2. Repeated LPS induced phosphorylation of Akt, and decreased
HDAC2 and Nrf2 expression
We examined the effects of i.n. LPS exposure on HDAC2 and
Nrf2 protein levels by western blotting. In our analysis, the mo-
lecular weight of HDAC2, Nrf2, Akt/p-Akt and β-actin in lung
homogenates matched with predicted band size of 55, 68, 60, and
42 kDa, respectively (Fig. 3A). When mouse lung was collected at
24 h after LPS exposure for 1 day, the level of HDAC2 was not al-
tered, but the expression of Nrf2 was signiﬁcantly increased. In
contrast, after LPS exposure on 3 consecutive days the expression
Fig. 2. Repeated exposure of LPS reduced the effect of FP on chemokine expression in BAL ﬂuid. Mice were intranasally administered with LPS and 0.05 mg/kg of FP for 1–3
days (A). Mice were intranasally treated with LPS and indicated dose of FP for 3 days (B), respectively. Twenty four hours after the last exposure of LPS, mice were sacriﬁced.
The CXCL1 levels in BAL ﬂuid were measured by ELISA. Results represent mean7SEM (n¼3, ###Po0.001, compared with control and vehicle group, **Po0.01, compared
with vehicle group and dosing groups).
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respectively, when compared with non-treatment controls. After
3 days exposure to LPS, HDAC2 and Nrf2 expression were de-
creased by 38.976.3% and 77.572.7% respectively, when com-
pared with LPS exposure for 1 d (Fig. 3A and B).Fig. 3. LPS exposure for 3 days reduced HDAC2, Nrf2 levels, and increased Akt phospho
administration, sacriﬁced. Lung homogenate was separated on SDS-PAGE, and the HDAC
HDAC2, Nrf2, Akt/p-Akt and β-actin were preliminary detected with predicted band siz
(D) and β-actin in the lung homogenates. Lower panel shows the ratios of HDAC2/β-actin
represent mean7SEM (n¼3, #Po0.05, ##Po0.01, ###Po0.001, compared with controWe also examined the effect of LPS exposure on Akt phos-
phorylation at Ser-473 as a marker of the activation of PI3K sig-
naling pathway. In mouse lung collected at 24 h after 1, 2 or
3 consecutive days exposure of LPS, there was an increase in
p-Akt/Akt ratios by 2.5-, 7.6- and 10.3-fold compared with that inrylation. Mice were administered with LPS for 1–3 days, and one day after the last
2, Nrf2, Akt, p-Akt, and β-actin protein levels were determined by immunoblotting.
e (A). Upper panel shows a typical immunoblot of HDAC2 (B), Nrf2 (C), Akt, p-Akt
(B), Nrf2/β-actin (C) or p-Akt/Akt (D), calculated by measuring band density. Results
l and dosing groups).
Fig. 4. PI3K inhibition restored the corticosteroid responsiveness in mice exposed with LPS. Mice were administered with LPS, and theophylline (A, B) or IC87114 (C, D) for
3 days, respectively. Twenty four hours after the last exposure of LPS, mice were sacriﬁced. The neutrophil numbers in BAL ﬂuid were analyzed by ﬂow cytometry (A, C). The
CXCL1 levels in BAL ﬂuid were measured by ELISA (B, D). Results represent mean7SEM (n¼3, ###Po0.001, compared with control and vehicle group, *Po0.05, ***Po0.001,
compared with vehicle group and dosing groups).
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suggesting the increase in p-Akt/Akt ratio is due to an increase of
phosphorylation levels.
3.3. Effect of PI3Kδ inhibitor on LPS-induced corticosteroid-in-
sensitive airway inﬂammation
After an i.n. exposure of LPS on 3 consecutive days, theophyl-
line (2.0 mg/mL, i.n.), an allosteric PI3Kδ inhibitor, or IC87114
(4.0 mg/mL, i.n.), a selective PI3Kδ speciﬁc small molecule in-
hibitor, were administered twice daily before daily LPS adminis-
tration. Theophylline alone did not suppress the increase in neu-
trophils or CXCL1 levels in BAL ﬂuid from mice with repeated LPS
exposure for 3 days and FP alone did not have any effects, either, as
previously presented (Fig. 4A and B). In contrast, a combination of
theophylline and FP signiﬁcantly suppressed LPS-induced airwayneutrophilia in BAL ﬂuid from 22.571.8104 cells/mL to 7.97
0.5104 cells/mL and also elevation of CXCL1 levels in BAL ﬂuid
from 214.6720.6 pg/mL to 61.9713.3 pg/mL. Combination treat-
ment with IC87114 and FP also signiﬁcantly suppressed LPS-in-
duced accumulation of neutrophils from 16.870.7104 cells/mL
to 5.970.3104 cells/mL and CXCL1 from 182.474.6 pg/mL to
71.472.7 pg/mL, although IC87114 alone did not affect neu-
trophils and CXCL1 (Fig. 4C and D). These data suggest that PI3Kδ
activation contributes to the corticosteroid insensitivity in mice
induced by 3 days exposure of LPS.4. Discussion
Corticosteroid resistance is one of major barriers of effective
management of chronic inﬂammatory respiratory diseases such as
K. Ueda et al. / Biochemistry and Biophysics Reports 7 (2016) 367–373372COPD and severe asthma [1–4]. In addition, respiratory RNA viruses,
such as human rhinovirus, respiratory syncytial virus, inﬂuenza virus,
are common causes of COPD and asthma exacerbations [16–20]. We
have previously reported that repeated doses of poly(I: C), which
mimics RNA virus infection, attenuated the anti-inﬂammatory effect
of corticosteroids in mice [25]. Bacterial infections, such as Haemo-
philus inﬂuenzae and Streptococcus pneumoniae, also cause exacer-
bations in patients with COPD. In the present study, we examined
whether repeated stimulation with LPS induced corticosteroid re-
sistance in airway inﬂammation in mice. The data clearly indicated
that repeated exposure of LPS on 3 consecutive days induced corti-
costeroid insensitive neutrophil accumulation and CXCL1 induction
in BAL ﬂuid although airway inﬂammation after LPS exposure for
1 day remained corticosteroid sensitive (Figs. 1 and 2). Therefore,
repeated inﬂammatory stimulation by LPS may result in the
attenuation of anti-inﬂammatory effects of corticosteroids. Some
investigators have reported that LPS induces internalization of Toll-
like receptor (TLR)–4, leading down-regulation of cell surface TLR4
and tolerance of LPS in peritoneal macrophages from C57BL/6 mice
or human peripheral blood monocytes [26–28]. In current study,
however, repeated exposure of LPS ampliﬁed inﬂammatory re-
sponses in A/J mice (Figs. 1 and 2). In addition, other groups also
reported that low dose LPS augmented pro-inﬂammatory cytokine
expression in murine bone marrow-derived macrophages and a
human macrophage cell line [29,30]. Thus, further studies on why
repeated LPS stimuli induce corticosteroid-insensitive inﬂammation
rather than the LPS tolerance in our model are needed.
We also demonstrated that intranasal administration of LPS for
3 days resulted in a decrease in HDAC2 (Fig. 3B). There is also a
marked reduction of HDAC2 activity and expression in lungs from
patients with COPD [31]. In HDAC2 knock-out mice, corticosteroids
have less effect on LPS induced airway inﬂammation [32]. HDAC2
has also been shown to be a prerequisite molecule of corticoster-
oid action as activated GR recruits HDAC2 molecule and inhibits
NF-κB-dependent pro-inﬂammatory gene expression by deacety-
lation of histones in epithelial and mononuclear culture cells in
vitro [33–37]. Thus, HDAC2 reduction observed after LPS treatment
on 3 consecutive days likely explains the molecular mechanism of
corticosteroid-insensitivity in repeated LPS-induced airway in-
ﬂammation. In this study, Nrf2 levels were also decreased after
repeat doses of LPS (Fig. 3C). Nrf2 knockout mice also showed
an impaired response to corticosteroids on airway inﬂammation
induced by LPS [32]. As HDAC2 is also known as a protein deace-
tylase, HDAC2 down-regulation causes Nrf2 acetylation, resulting
in decreased stability and activity of Nrf2 in macrophages [13],
which causes reduction of anti-oxidant capacity in cells and am-
pliﬁcation of oxidative stress. Ampliﬁed oxidative stress might
decrease HDAC2 further as oxidative stress such as H2O2 and ci-
garette smoke conditioned media are reported to decrease HDAC2
protein expression via protein modiﬁcations, such as phosphor-
ylation, ubiquitination and nitration [11,38,39]. Notably, viral or
bacterial infection or LPS exposure are reported to induce oxida-
tive stress in cells [40,41].
Furthermore, we also demonstrated that the level of phos-
phorylation of Akt was increased after repeated exposure to LPS,
which indicates the activation of PI3K signaling pathway (Fig. 3D).
Thus, our study suggests that time-dependent decrease in HDAC2
and Nrf2 are inversely-related to the p-Akt phosphorylation levels,
and the activation of PI3K signaling pathway causes corticosteroid
insensitivity through a decrease in HDAC2 and Nrf2 levels. PI3Kδ is
activated by oxidative stress, such as cigarette smoke in vivo and
cigarette smoke extract in vitro, and negatively regulates the
HDAC2 activity via Akt phosphorylation, which contributes to the
attenuation of anti-inﬂammatory effects of corticosteroids [8,42].
Our results showed that both theophylline and IC87114, which are
allosteric and a δ isoform-selective PI3K inhibitors, respectively,restored the effects of FP on repeated LPS exposure-induced air-
way neutrophilia and elevation of CXCL1 in BAL ﬂuid (Fig. 4). This
is in agreement with the fact that these PI3K inhibitors restored
corticosteroid sensitivity in cigarette smoke exposed mice [8].
Another report also suggests that PI3Kδ and Akt activation in-
duced by oxidative stress cause corticosteroid insensitivity via the
activation of mammalian target of rapamycin independently in the
HDAC2 activity [43]. Thus, in the present corticosteroid-refractory
murine model, repeated dosed LPS induced PI3Kδ-dependent
decrease in HDAC2 and Nrf2 may, at least in part, contributes to
the corticosteroid insensitive airway inﬂammation.
In conclusion, we report that repeated LPS exposure induced
corticosteroid refractory airway inﬂammation potentially via a
decrease in HDAC2 and Nrf2 expression by PI3Kδ activation. Un-
derstanding the molecular mechanisms of corticosteroid re-
sistance may result in the development of new therapeutic stra-
tegies to treat diseases characterized by corticosteroid resistant
inﬂammation. The mouse model we describe with repeated LPS
exposure may prove to be a useful in vivo model to assess the
effects of novel therapies.Appendix A. Transparency document
Transparency document associated with this article can be
found in the online version at http://dx.doi.org/10.1016/j.bbrep.
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